

MEDIA STATEMENT

PHILOGEN SPA ANNOUNCES PARTICIPATION TO THE “FEDERATION OF CLINICAL IMMUNOLOGY SOCIETIES (FOCIS) ANNUAL MEETING 2017”, JUNE 14-17, 2017, CHICAGO, USA

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “[FOCIS Annual Meeting 2017](#)” that will take place at the Hilton Chicago Hotel in Chicago from June 14 to June 17, 2017.

The meeting, organized by the Federation of Clinical Immunology Societies, will gather leading clinicians and researchers to deliver the latest breakthroughs across immune-mediated diseases.

Prof. Dr. Dario Neri, Swiss Federal Institute of Technology Zurich, co-founder and Chairman of the scientific advisory board of Philogen, will give a talk during the “*Cancer Immunity & Immunotherapy Course*” organized in collaboration with the Society for Immunotherapy of Cancer (SITC). The lecture with the title “[Focus on Engineered Antibodies](#)” is scheduled for Wednesday, June 14 in the “*Checkpoint Blockade, Combination Therapies*” section.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

About the Philogen group

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com
